Anti-High MW Kininogen Light Chain Antibody (20001)

$623.00

Host Quantity Applications Species Reactivity Data Sheet  
Mouse 200ug WB,ELISA,coagulation assays Human
SKU: 20001 Categories: , ,
Overview
Product Name Anti-High MW Kininogen Light Chain Antibody (20001)
Description Anti-High MW Kininogen - Light Chain Mouse Monoclonal Antibody
Target High MW Kininogen Light Chain
Species Reactivity Human
Applications WB,ELISA,coagulation assays
Host Mouse
Clonality Monoclonal
Clone ID C11C1
Isotype IgG1
Immunogen Purified human high molecular weight kininogen.
Properties
Form Liquid
Concentration Lot Specific
Formulation PBS, pH 7.4.
Buffer Formulation Phosphate Buffered Saline
Buffer pH pH 7.4
Format Purified
Purification Purified by Protein G affinity chromatography
Specificity Information
Specificity This antibody recognizes an epitope on the unique 46kDa light chain of human HMWK. The epitope maps to domain 5 of human HMWK. It can completely neutralize the coagulant activity of human HMWK.
Target Name Kininogen-1
Target ID High MW Kininogen Light Chain
Uniprot ID P01042
Alternative Names α-2-thiol proteinase inhibitor, Fitzgerald factor, High molecular weight kininogen, HMWK, Williams-Fitzgerald-Flaujeac factor [Cleaved into: Kininogen-1 heavy chain; T-kinin
Gene Name KNG1
Sequence Location Secreted, extracellular space.
Biological Function (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Research Areas Coagulation factors.
Background High molecular weight kininogen (HMWK) is a circulating plasma protein which participates in the initiation of blood coagulation, and in the generation of the vasodilator bradykinin via the Kallikrein-kinin system. HMWK is inactive until it either adheres to binding proteins beneath an endothelium disrupted by injury, thereby initiating coagulation, or it binds to intact endothelial cells or platelets for functions other than coagulation. HMWK is an alpha-globulin with six functional domains. It circulates as a single-chain 626 amino acid polypeptide . The heavy chain contains domains 1, 2, and 3; the light chain, domains 5 and 6. Domain 4 links the heavy and light chains.
Application Images
Description Immunoblot with #20001 on (A) normal human plasma, (B) HMWK-deficient plasma, and (C) purified HMWK
Additional Information
Handling
Storage This antibody is stable for at least one (1) year at -20°C.
Dilution Instructions Dilute in PBS or medium that is identical to that used in the assay system.
Application Instructions This antibody may be used in ELISA and Western blots to detect human HMWK light chain. It may also be used in coagulation assays.

Enduser should determine optimal antibody concentrations for their applications.
References & Data Sheet
References Schmaier et al. (1987) Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. Journal of Biological Chemistry 262: 1405-1411.
Espinola et al. (2004) A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. American Journal of Pathology 165: 969-976.
Keith et al. (2005) A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat.
Arthritis Research and Therapy 7: R769-R776. Khan et al. (2010) Inhibition of metastasis of syngeneic murine melanoma in vivo and vasculogenesis in vitro by monoclonal antibody C11C1 targeted to domain 5 of high molecular weight kininogen. Cancer Immunology and Immunotherapy 59: 1885-1893.